Objective:

Analyzing the clinical characteristics, potential mechanisms, and treatment strategies of pembrolizumab-induced immune-related hepatitis.

Approach:

Key Findings:

• Among the 42 patients, 27 were male and 14 were female, with an average age of 64.2 years.
• Clinical manifestations included liver toxicity, neurological symptoms, skin reactions, systemic symptoms, and digestive symptoms.
• The time from initiation of pembrolizumab to hepatitis onset varied from 2 to 630 days.
• Corticosteroids were the primary treatment for immune-related hepatitis.
• Pathogenesis may relate to dysregulation of liver immune tolerance as noted in the source.

Interpretation:

Limitations:

• Causal conclusions cannot be drawn due to lack of denominator data and potential reporting bias as stated in the source.
• The study is limited to case reports, which may not represent the broader patient population.

Conclusion:

Further research is suggested in the source to better understand pembrolizumab-induced immune-related hepatitis.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.